Recursion Pharmaceuticals Stock Forecast
NASDAQ: RXRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 4.26 -0.23%
RXRX analyst consensus
Consensus (7 analysts)
none
Avg. price target
$7.22+69.09%
- Strong buy 2
- Buy 1
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering Recursion Pharmaceuticals (2026-10-07), 3 rate the stock a buy or strong buy, 4 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $7.22, with a high estimate of $10.00 and a low estimate of $4.00. The average target implies upside of 69.1% from the current price of $4.27.
The spread between the highest and lowest targets is 150.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for RXRX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 29% |
| Buy | 1 | 14% |
| Hold | 4 | 57% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $4.00 | -6.32% |
| Average target | $7.22 | +69.09% |
| High target | $10.00 | +134.19% |